Literature DB >> 8531836

The macrophage-T-lymphocyte theory of schizophrenia: additional evidence.

R S Smith1, M Maes.   

Abstract

Chronically activated macrophages and T-lymphocytes, along with excessive interleukin-2 and other cytokine secretions, were previously proposed as the fundamental mediators of schizophrenia. This paper provides further support for the immune model of schizophrenia, including evidence on neurotransmitter abnormalities, the low amplitude of the auditory P300 event-related potential, the neurodevelopmental model of schizophrenia and the possible involvement of the locus ceruleus in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531836     DOI: 10.1016/0306-9877(95)90062-4

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  43 in total

Review 1.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

2.  Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; Heidi Ormstad; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

3.  Markers of inflammation in schizophrenia: association vs. causation.

Authors:  Peter Manu; Christoph U Correll; Martien Wampers; Alex J Mitchell; Michel Probst; Davy Vancampfort; Marc De Hert
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

4.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

5.  Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis.

Authors:  Xinyu Fang; Yi Zhang; Weixing Fan; Wei Tang; Chen Zhang
Journal:  Mol Neuropsychiatry       Date:  2017-10-28

6.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

7.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 8.  Biological indicators of suicide risk in youth with mood disorders: what do we know so far?

Authors:  Ute Lewitzka; Sarah Doucette; Florian Seemüller; Paul Grof; Anne C Duffy
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

9.  In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome.

Authors:  Michael Maes; Buranee Kanchanatawan; Sunee Sirivichayakul; André F Carvalho
Journal:  Mol Neurobiol       Date:  2018-11-27       Impact factor: 5.590

10.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.